JPMorgan Chase Reveals Market Update – This Stock Could Surge 116%
According to a note sent to clients by global investment strategist Madison Faller, JPMorgan Chase has a positive outlook despite a recent dip in the stock market. Financial technology firm TipRanks reports that Faller s...
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
According to a note sent to clients by global investment strategist Madison Faller, JPMorgan Chase has a positive outlook despite a recent dip in the stock market. Financial technology firm TipRanks reports that Faller sees both opportunities and risks in the current economic climate, but remains optimistic overall. Faller also notes that volatility is a normal part of the market.
Investors panic and miss out on accumulationThe stock market has experienced a 3.8% decrease in the last month, which has caused investors to panic and miss out on potential opportunities to buy low.
Faller suggests that instead of selling during dips, investors should take advantage of the fear and uncertainty in the market to make beneficial investments.
Similarly, in the crypto markets, JPMorgan Chase managing director Nikolaos Panigirtzoglou believes that a recent correction has resulted in limited downside, according to a report by Bloomberg.
According to Panigirtzoglou, the long-position liquidations are largely over, and “as a result, we see limited downside for crypto markets over the near term.”
Regarding individual stocks, according to TipRanks, Telephone & Data Systems (TDS) is a favorite of JPMorgan analyst Philip Cusick. TDS experienced a surge after the company announced its intention to sell its 83% stake in US Cellular.
Although the company’s earnings and sales during the second quarter fell short of expectations, Cusick believes that the restructuring could lead to a rally from $17.59 to $38 within a year, indicating a potential increase of 116%.
Moreover, JPMorgan analyst Eric Joseph predicts that HilleVax (HLVX), a vaccine development firm in the clinical stage, could see a significant increase in value as the company’s vaccines progress through trial stages.
Joseph has set a price target of $22, which is a 69% increase from its current price of $13.
Stay tuned for more news and make sure to keep your eyes peeled on the crypto market.
Why this matters
This cryptocurrency story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on CryptoGazetteRelated market context
Norway Holds $400M in Bitcoin via Indirect Stock Exposure
Key Takeaways: Norway’s Government Pension Fund Global holds about $400 million in ind.rect BTC and ETH The fund does not directly...
JPMorgan Cuts Polymarket Banking Ties Amid Regulatory Concerns and $20B Valuation
Key Takeaways: In October 2025, JPMorgan apparently broke its ties with Polymarket because of regulatory issues. Since then, Polym...
How a public crypto firm’s 4.3% AI gain hides millions in balance sheet losses
SRX Global reported a 4.3% EMJX gain that the company labels hypothetical, but its first post-acquisition disclosures still leave...
Another public company abandons Bitcoin playbook after treasury volatility drove $22 million loss
KULR Technology Group has exited Bitcoin mining, repaid its Coinbase debt, and begun selling its BTC holdings as the battery techn...
Bitcoin’s $16.3 billion Wall Street stress test splits into four positional patterns
The $16.3 billion in Bitcoin ETF positions that CryptoSlate recently tracked ahead of the Q2 filing deadline resolved into four di...
Strategy tells MSCI ‘Bitcoin doesn’t need you’ as $2.8 billion index risk hangs over MSTR
Strategy faces a renewed threat of removal from major MSCI equity indexes under a broader screening proposal that could trigger an...